Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Merola

Showing results (301-310 of 394) with videos related to

Pageof 40
Sort By:
The Journal of Rheumatology|April 16, 2022
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE StudyTien Nguyen, Melvin Churchill, Robert Levin, et al.
The New England Journal of Medicine|October 19, 2017
Tofacitinib or Adalimumab versus Placebo for Psoriatic ArthritisPhilip Mease, Stephen Hall, Oliver FitzGerald, et al.
The Journal of Investigative Dermatology|October 3, 2024
A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring SystemMaria C Schneeweiss, Robert J Glynn, Richard Wyss, et al.
RMD Open|September 28, 2022
Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritisLaura C Coates, Josef S Smolen, Philip J Mease, et al.
Rheumatology and Therapy|September 8, 2022
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation AnalysisKurt de Vlam, Philip J Mease, Andrew G Bushmakin, et al.
RMD Open|March 10, 2026
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studiesPhilip J Mease, Joseph F Merola, Marina Magrey, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Single Cell Analysis of pBMCs of Psoriasis patients reveals distinct CD4+ T cell phenotypes associated with response to IL-23 blockadeKathryne E Marks, Anina Sun, Ifeoluwakiisi Adejoorin, et al.
Rheumatology and Therapy|August 19, 2023
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryPhilip J Mease, Alexis Ogdie, John Tesser, et al.
Dermatology and Therapy|February 15, 2022
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17April W Armstrong, Andrew Blauvelt, Ulrich Mrowietz, et al.
The Journal of Investigative Dermatology|January 26, 2025
Construct Validity of the IDEOM Musculoskeletal Questionnaire: An Instrument to Measure Musculoskeletal Symptoms in Patients with Psoriatic DiseaseLourdes M Perez-Chada, George Gondo, Carly Grant, et al.
Pageof 40

Showing results (301-310 of 394) with videos related to

Sort By:
Pageof 40
The Journal of Rheumatology|April 16, 2022
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE StudyTien Nguyen, Melvin Churchill, Robert Levin, et al.
The New England Journal of Medicine|October 19, 2017
Tofacitinib or Adalimumab versus Placebo for Psoriatic ArthritisPhilip Mease, Stephen Hall, Oliver FitzGerald, et al.
The Journal of Investigative Dermatology|October 3, 2024
A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring SystemMaria C Schneeweiss, Robert J Glynn, Richard Wyss, et al.
RMD Open|September 28, 2022
Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritisLaura C Coates, Josef S Smolen, Philip J Mease, et al.
Rheumatology and Therapy|September 8, 2022
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation AnalysisKurt de Vlam, Philip J Mease, Andrew G Bushmakin, et al.
RMD Open|March 10, 2026
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studiesPhilip J Mease, Joseph F Merola, Marina Magrey, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Single Cell Analysis of pBMCs of Psoriasis patients reveals distinct CD4+ T cell phenotypes associated with response to IL-23 blockadeKathryne E Marks, Anina Sun, Ifeoluwakiisi Adejoorin, et al.
Rheumatology and Therapy|August 19, 2023
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryPhilip J Mease, Alexis Ogdie, John Tesser, et al.
Dermatology and Therapy|February 15, 2022
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17April W Armstrong, Andrew Blauvelt, Ulrich Mrowietz, et al.
The Journal of Investigative Dermatology|January 26, 2025
Construct Validity of the IDEOM Musculoskeletal Questionnaire: An Instrument to Measure Musculoskeletal Symptoms in Patients with Psoriatic DiseaseLourdes M Perez-Chada, George Gondo, Carly Grant, et al.
Pageof 40